全球纖維瘤市場：區域與國家分析與預測（2025-2035）

纖維瘤市場的主要成長要素之一是標靶治療的進步。

隨著對纖維瘤的分子和遺傳促進因素的深入了解，各公司正在開發更精準、更個性化的治療方法，這些療法針對參與腫瘤生長的特定通路，例如 EZH2 抑製劑 Tazemetostat (EPZ-6438) 和靶向 Notch 訊號通路的 AL102。這些治療方法比傳統化療具有療效更高、副作用更少的潛力，對患者和醫療保健提供者而言極具吸引力。

罕見疾病的監管支持也推動了市場的成長。孤兒藥認定和加速核准等監管激勵措施正在鼓勵新治療方法的開發，進一步加速了市場的成長。隨著更有效的標靶治療的廣泛應用，患者越來越尋求早期診斷和專科治療，這反過來又增加了治療需求。人們對纖維瘤認知的提高以及個人化醫療的進步預計將幫助市場保持成長勢頭，為患有這種罕見且極具挑戰性的疾病的患者帶來希望。

然而，仍存在一些挑戰，阻礙著其發展。最大的挑戰之一是FDA核准的專門針對纖維瘤的治療方法數量仍然有限。儘管Tazemetostat (EPZ-6438)和AL102等藥物取得了一些進展，但許多患者仍依賴仿單標示外用藥或手術、放射線治療等侵入性治療。缺乏核准的標準治療方法限制了患者獲得有效、個人化治療的機會，尤其是在臨床試驗和專科護理機會有限的地區。

另一個重大挑戰是纖維瘤的高復發率。即使透過手術或放射線治療暫時切除腫瘤，腫瘤也經常復發，有時甚至會以更具侵襲性的形態出現。這種難以預測的復發趨勢使得長期治療變得困難，迫使患者反覆接受治療，這對身心都造成極大的負擔。

此外，該疾病的罕見性和複雜性使其診斷和治療更加困難。許多醫生可能對纖維瘤缺乏了解，尤其是在早期階段，這可能導致診斷延誤和對治療的焦慮。民眾和醫護人員也缺乏相關認知，限制了早期療育的機會。

最後，成本和獲得新治療方法的機會也是障礙：像他澤美司他這樣的標靶治療非常昂貴，對於沒有足夠保險或經濟資源的患者來說，持續治療和參與臨床試驗的費用非常高。

本報告調查了全球纖維瘤市場，並總結了主要趨勢、市場影響因素分析、法律制度、臨床試驗趨勢、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局以及主要企業的概況。

目錄

執行摘要

第1章全球纖維瘤市場：產業展望

• 市場趨勢
• 法律規範
• 流行病學分析
• 臨床試驗分析
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場挑戰
  • 市場機會

2. 全球纖維瘤市場（按地區）

• 北美洲
  • 主要發現
  • 市場動態
  • 市場規模及預測
• 歐洲
  • 主要發現
  • 市場動態
  • 市場規模及預測
• 亞太地區
  • 主要發現
  • 市場動態
  • 市場規模及預測

3. 全球纖維瘤市場：競爭格局與公司概況

• 主要策略和發展
  • M&A
  • 協同活動
  • 業務擴展和資金籌措
  • 產品發布和核准
  • 其他活動
• 公司簡介
  • SpringWorks Therapeutics
  • Ayala Pharmaceuticals
  • Puma Biotechnology
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Ipsen
  • Deciphera Pharmaceuticals

第4章調查方法

Global Desmoid Tumors Market, Analysis and Forecast: 2025-2035

Desmoid Tumors are non-cancerous (benign) fibrous growths that arise from connective tissue, often in the muscles, tendons, or abdominal wall. Despite being benign, they can be locally aggressive, meaning they may grow and invade nearby tissues, causing significant health issues. These tumors are characterized by the abnormal growth of fibroblasts, the cells that produce collagen, which leads to the formation of dense, fibrous masses.

Desmoid tumors are rare and account for less than 3% of all soft tissue tumors. They can develop in any part of the body but are most found in the abdomen, muscles, and limbs. Although they do not metastasize (spread to other parts of the body), their growth can cause pain, discomfort, and, in some cases, can impact the function of nearby organs or muscles.

The exact cause of Desmoid Tumors is not fully understood, but they are often associated with genetic mutations, especially in the APC gene that is involved in regulating cell growth. They are also more commonly found in individuals with Familial Adenomatous Polyposis (FAP), a hereditary condition that increases the risk of various tumors.

Symptoms of Desmoid Tumors vary depending on their size and location and can include pain, swelling, or restricted movement. Treatment options include surgery, radiation therapy, and targeted drug therapies, with the goal of controlling tumor growth and preventing recurrence, as these tumors often have high recurrence rates.

One of the key drivers of the Desmoid Tumors market is the advancement of targeted therapies. As the understanding of the molecular and genetic drivers of Desmoid Tumors improves, companies are developing more precise, personalized treatments that target the specific pathways involved in tumor growth, such as EZH2 inhibition with drugs like Tazemetostat (EPZ-6438) and Notch signaling with therapies like AL102. These treatments offer the potential for greater efficacy with fewer side effects compared to traditional approaches like chemotherapy, making them a highly attractive option for patients and healthcare providers alike.

Additionally, regulatory support for rare diseases, such as Orphan Drug Designation and accelerated approval processes, is encouraging the development of new therapies, further propelling Desmoid tumors market growth. As more effective, targeted treatment options become available, patients are more likely to seek early diagnosis and specialized care, increasing the demand for these therapies. Combined with the growing awareness of Desmoid Tumors and the rise in personalized medicine, the Desmoid Tumors market is expected to continue its growth trajectory, offering hope to patients with this rare and challenging condition.

Despite the growth of the Desmoid Tumors market, several challenges continue to hinder its progress. One of the primary challenges is the limited number of FDA-approved treatments specifically for Desmoid Tumors. While there has been progress with drugs like Tazemetostat (EPZ-6438) and AL102, the treatment landscape remains relatively underdeveloped, as many patients still rely on off-label medications or invasive treatments like surgery or radiation therapy. This lack of approved, standardized therapies means that many patients may not have access to effective, tailored treatments, especially in areas where clinical trials or specialized care are not readily available.

Another significant challenge is the high recurrence rate of Desmoid Tumors. Even after surgical removal or radiation therapy, Desmoid Tumors often return, sometimes in a more aggressive form. This unpredictability makes long-term management difficult and can lead to repeated treatments, causing both physical and emotional strain on patients.

Additionally, the rarity of the condition and its complex nature can make diagnosis and treatment challenging for healthcare providers. Many doctors may be unfamiliar with Desmoid Tumors, especially in the early stages, leading to potential delays in diagnosis and a lack of confidence in managing the disease. This is compounded by insufficient awareness among the general public and healthcare professionals, which further limits early intervention opportunities.

Finally, cost and accessibility of emerging treatments are also obstacles. Targeted therapies like Tazemetostat are expensive, and the costs associated with ongoing treatment, including clinical trial participation, may be prohibitive for some patients, particularly those without adequate insurance coverage or financial support.

These challenges present significant barriers to the Desmoid tumors market's full growth potential, requiring continued research, regulatory support, and advancements in treatment options to overcome them.

The global Desmoid Tumors market is highly competitive, with several leading companies driving innovation and market growth, such as SpringWorks Therapeutics, Ayala Pharmaceuticals, Ipsen, Deciphera Pharmaceuticals, and Bristol-Myers Squibb. These companies are at the forefront of developing novel therapies to address the unmet needs of patients with this rare condition. SpringWorks Therapeutics is advancing Tazemetostat (EPZ-6438), an EZH2 inhibitor, which is showing promise in treating Desmoid Tumors by targeting the molecular pathways that drive tumor growth. Similarly, Ayala Pharmaceuticals is focusing on AL102, a gamma-secretase inhibitor that targets the Notch signaling pathway, a key driver in Desmoid Tumor formation. Ipsen is investigating Cabometyx (cabozantinib), a multi-kinase inhibitor, for its potential to treat Desmoid Tumors, while Deciphera Pharmaceuticals is developing Ripretinib, a kinase inhibitor that targets resistant tumors. Additionally, Bristol-Myers Squibb is exploring the use of Opdivo (nivolumab), an immune checkpoint inhibitor, for Desmoid Tumors, aiming to harness the power of immunotherapy. These innovations are paving the way for more targeted, effective treatments that offer hope for better management and outcomes for patients with Desmoid Tumors.

Desmoid Tumors Market Segmentation:

Segmentation 1: by Region

• North America
• Europe
• Asia-Pacific

The global Desmoid Tumors market is undergoing significant transformation, fueled by emerging trends that are reshaping the treatment landscape and expanding patient access. One key trend is the advancement of targeted therapies, such as Tazemetostat (EPZ-6438) and AL102, which focus on specific molecular pathways like EZH2 inhibition and Notch signaling. These therapies offer a more precise approach to treating Desmoid Tumors, reducing the side effects typically associated with traditional treatments like chemotherapy. Additionally, personalized medicine is gaining momentum, with therapies being tailored to the unique genetic profiles of patients, improving treatment efficacy and minimizing adverse effects.

Another important trend is the increased participation in clinical trials. As awareness of Desmoid Tumors grows, more patients are enrolling in clinical trials, which accelerates the development and approval of new therapies. Regulatory support, such as Orphan Drug Designation, is also fueling Desmoid tumors market growth by providing incentives for companies to develop treatments for rare diseases like Desmoid Tumors.

The rise of digital health tools and telemedicine is further transforming the landscape, making treatment and monitoring more accessible, especially in underserved areas. These technologies are improving patient engagement and allowing for more efficient management of the condition. Overall, these emerging trends are driving the growth of the Desmoid Tumors market, improving outcomes for patients, and providing new opportunities for pharmaceutical companies and researchers to address this rare and complex disease.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Desmoid Tumors Market: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology Analysis
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Desmoid Tumors Market (Region), ($Billion), 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Desmoid Tumors Market, by Country
      • 2.1.3.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Desmoid Tumors Market, by Country
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 U.K.
      • 2.2.3.1.3 France
      • 2.2.3.1.4 Italy
• 2.3 Asia Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia Pacific Desmoid Tumors Market, by Country
      • 2.3.3.1.1 China
      • 2.3.3.1.2 Japan

3. Global Desmoid Tumors Market: Competitive Landscape and Company Profiles

• 3.1 Key Strategies and Development
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Synergistic Activities
  • 3.1.3 Business Expansions and Funding
  • 3.1.4 Product Launches and Approvals
  • 3.1.5 Other Activities
• 3.2 Company Profiles
  • 3.2.1 SpringWorks Therapeutics
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers/End-Users
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Ayala Pharmaceuticals
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers/End-Users
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 Puma Biotechnology
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers/End-Users
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 Bristol-Myers Squibb
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products / Product Portfolio
    • 3.2.4.3 Top Competitors
    • 3.2.4.4 Target Customers/End-Users
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View
  • 3.2.5 Eli Lilly and Company
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products / Product Portfolio
    • 3.2.5.3 Top Competitors
    • 3.2.5.4 Target Customers/End-Users
    • 3.2.5.5 Key Personnel
    • 3.2.5.6 Analyst View
  • 3.2.6 Ipsen
    • 3.2.6.1 Overview
    • 3.2.6.2 Top Products / Product Portfolio
    • 3.2.6.3 Top Competitors
    • 3.2.6.4 Target Customers/End-Users
    • 3.2.6.5 Key Personnel
    • 3.2.6.6 Analyst View
  • 3.2.7 Deciphera Pharmaceuticals
    • 3.2.7.1 Overview
    • 3.2.7.2 Top Products / Product Portfolio
    • 3.2.7.3 Top Competitors
    • 3.2.7.4 Target Customers/End-Users
    • 3.2.7.5 Key Personnel
    • 3.2.7.6 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Desmoid Tumors Market (by Region), $Billion, 2024 and 2035
• Figure: Global Desmoid Tumors Market Key Trends, Analysis

List of Tables

• Table Global Desmoid Tumors Market Dynamics, Impact Analysis
• Table Global Desmoid Tumors Market (by Region), $Billion, 2024-2035